Navigation Links
Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1/2 Study of MM-111, a Bispecific Antibody to ErbB2/3
Date:7/6/2009

e range of tumor types and we are hopeful this will translate into patient benefit. START and Fox Chase are outstanding cancer research centers and we are excited to be working with leading clinical investigators at both institutions."

Merrimack has developed a broad intellectual property position around its oncology therapeutic portfolio, including its bispecific antibody technology and MM-111. This portfolio includes U.S. and international patent filings relating to compositions of matter and methods of use as well as licensed patents and pending patent applications, trade secrets and proprietary know-how.

About Merrimack
Merrimack Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of novel treatments for cancer and autoimmune disease. Its first two oncology pipeline candidates, MM-121 and MM-111, are currently in Phase 1 clinical development. The Company's proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, enables the high-throughput profiling of protein networks as a basis for improved validation, lead identification and speed in the development of innovative, effective and well tolerated therapeutics. MM-121 and MM-111 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. Merrimack is a privately-held company based in Cambridge, Massachusetts.

Contact:
Kathleen Petrozzelli, Corporate Communications, 617-441-1043, kpetrozzelli(at)merrimackpharma.com     http://www.merrimackpharma.com

Betsy Stevenson, RaymondStevenson Healthcare, 860-984-1424, betsy(at)raymondstevenson.com

###

Read the full story at http://www.prweb.com/relea
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2 3 4

Related medicine news :

1. Endo Pharmaceuticals to Announce Second Quarter 2009 Financial Results on July 30, 2009
2. Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial
3. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM211, a Novel Product Candidate for the Treatment of Respiratory Diseases
4. Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Products
5. Lotus Pharmaceuticals, Inc. Again Awarded GSP Certification
6. Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Greece by SpePharm
7. Biostar Pharmaceuticals, Inc. Begins Construction of Raw Material Processing Facility of the Herbal Plantation Base
8. Watson Pharmaceuticals Receives FDA Approval For Generic PLAN B(R)
9. The Crohns & Colitis Foundation and Procter & Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners
10. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Vascular Imaging Applications of Its PS-Targeting Platform
11. DiaGenic to Provide MCI Biomarkers for Merz Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1/2 Study of MM-111, a Bispecific Antibody to ErbB2/3
(Date:9/21/2014)... While public health authorities focus on the physical activity ... University of Montreal reveals that for children, playing has ... an activity that is fun, done alone or with ... or pleasure, but also to combat boredom, sadness, fear, ... of play, authorities put aside several aspects of play ...
(Date:9/21/2014)... roasted peanuts are more likely to trigger an allergy ... study involving mice. , The researchers say that specific ... dry roasting process are recognised by the body,s immune ... immune response the next time it sees any peanuts. ... number of people with peanut allergies in the Western ...
(Date:9/21/2014)... The Laboratory Testing Services industry is ... tests on items ranging from consumer and food products ... on operators to ensure the safety and quality of ... of government safety regulations and consumer lawsuits have led ... Although revenue briefly dipped in 2009 as the US ...
(Date:9/21/2014)... "I wanted to be able to obtain a ... energy drinks," said an inventor from Fresh Meadows, N.Y. ... plain, old coffee. That is why I came up ... CHEWING GUM to provide a healthy energy boost that ... nutritious vitamins, minerals and antioxidants. It also features a ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 The ... BHWG) will host a statewide symposium ( tinyurl.com/ILBHC14 ... Veterans, and their Families. Sponsored by the VNA ... Lottery Cash Grant, and Health & Disability Advocates, ... at the Hilton Hotel in Springfield, IL. ...
Breaking Medicine News(10 mins):Health News:Narrow focus on physical activity could be ruining kids' playtime 2Health News:Dry roasting could help trigger peanut allergy 2Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 2Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 3
... LUNA and the Breast Cancer Fund Launch National Campaign to Inspire ... Educate that Prevention is ... be diagnosed with breast cancer in their lifetime. Although 50 percent,of ... sufferers have a genetic history of the disease. LUNA, the ...
... Mich., Oct. 29 American,Physicians Capital, Inc. (Nasdaq: ... has authorized the repurchase of an additional $20,million of ... under Rule 10b5-1,of the Securities Exchange Act of 1934. ... dollars allocated to the 2007 10b5-1 plan,adopted by the ...
... to Ongoing Oncology Program for MDX-1106, PRINCETON, ... Medarex, Inc. (Nasdaq: MEDX ) announced today ... filed with the U.S. Food &,Drug Administration (FDA) ... Ltd.), a fully human anti-PD-1 antibody being,investigated for ...
... the 2007 third quarter includes $1.8 million of first ... commercial products, DUBLIN, Calif., Oct. 29 SuperGen ... the discovery, rapid,development and commercialization of therapies for solid ... third,quarter and nine months ended September 30, 2007. ...
... with first-ever attack, babies, and people with AIDS, guideline ... CT brain scans should be used to screen certain ... the right kind of treatment, according to a new ... The guideline authors analyzed all available scientific evidence on ...
... for evaluating the eyes ability to distinguish object details ... could provide a more accurate way to assess the ... devices and training, according to a Canadian study. The ... illumination targets for testing spatial vision, which the authors ...
Cached Medicine News:Health News:LUNA Pure Prevention Survey Confirms Breast Cancer Misconceptions 2Health News:LUNA Pure Prevention Survey Confirms Breast Cancer Misconceptions 3Health News:American Physicians Capital, Inc. Authorizes Additional $20 Million Share Buyback 2Health News:Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody 2Health News:Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody 3Health News:Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody 4Health News:SuperGen Reports 2007 Third Quarter Financial Results 2Health News:SuperGen Reports 2007 Third Quarter Financial Results 3Health News:SuperGen Reports 2007 Third Quarter Financial Results 4Health News:SuperGen Reports 2007 Third Quarter Financial Results 5Health News:SuperGen Reports 2007 Third Quarter Financial Results 6Health News:SuperGen Reports 2007 Third Quarter Financial Results 7Health News:SuperGen Reports 2007 Third Quarter Financial Results 8Health News:SuperGen Reports 2007 Third Quarter Financial Results 9Health News:SuperGen Reports 2007 Third Quarter Financial Results 10Health News:Certain Seizure Patients Need Emergency CT Scan 2Health News:Test for visual acuity could aid detection, rehabilitation of AMD 2
(Date:9/19/2014)... , Sept. 19, 2014 Kiromic, LLC, a ... of Kent Hance , the former chancellor of Texas ... retired as chancellor in July 2014, after raising $1.2 billion ... that Kent Hance , the most successful chancellor in ... team not only as an investor, but also as our ...
(Date:9/19/2014)... , September 19, 2014 ... by Equipment (Cryotherapy, Heat, therapy, Hydrotherapy), Accessories (Posture Mirror, ... (Hospitals), Advanced technologies - Global Forecast to 2019" ... poised to reach $19,786.3 Million by 2019 from ... 6.8% from 2014 to 2019. Browse ...
(Date:9/19/2014)... , Sept. 19, 2014  4WEB Medical announces ... 3D-printed foot and ankle osteotomy implants on the ... Ankle Society annual meeting in Chicago ... all of a surgeon,s osteotomy needs with 74 size options ... systems had smaller offerings of only 15 to 18 implant ...
Breaking Medicine Technology:Former Texas Tech Chancellor Named New Vice Chairman of the Board of Kiromic, LLC 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 44WEB Medical Unveils 3D-Printed Osteotomy Truss System 2
... ... pay the United States $1.375 million to resolve False Claims Act ... of a sham durable medical equipment (DME) provider, the Justice Department ... MediNet Corp. provided the kickbacks and assistance and, in return, Harborside ...
... Industry Distributors Association (HIDA) announces the launch of a ... value of medical products distribution. , "Nearly one hundred ... delivered by a distributor, yet few people understand the ... it more efficient," said Matthew J. Rowan, HIDA,s president ...
Cached Medicine Technology:Harborside Healthcare to Pay U.S. $1.375 Million to Resolve Allegations of Kickbacks and Sham Durable Medical Services 2
... Design Holds The Lens Securely During ... Blades Keep The Optic From Being ... Over Release Of The Optic.,Wide Jaw ... During Insertion.,Reusable, Autoclaveable, Made In The ...
... Unique In-Line Footplates Are Turned 90 ... The Diamond Blade While Incising Tissue. ,Special ... Blade Depth Penetration.,Pre-Set Blade Extension Settings ... Retraction And Full Extension.,1mm Wide Snub ...
2.5V Halogen source, fiber-optic delivery, 2.5X magnification....
Pocket-sized instrument with 2.5X magnification....
Medicine Products: